Skip to content
NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Glaukos Corp. GKOS

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$507.4M
▲ 32.3% YoY
$-187.7M
$-22.5M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Glaukos develops and commercializes dropless therapies and associated products for the treatment of glaucoma, corneal disorders, and retinal disease. As of December 31, 2025, it had 1,094 full-time employees. In 2025, sales to U.S. and international customers accounted for 74% and 26% of its net sales, respectively. It operates in one operating segment, and organizes its business around five principal novel platforms that address four therapeutic areas within ophthalmology: glaucoma, corneal disorders, anterior segment and posterior segment. Its iStent family of products comprises three commercialized micro-scale surgical devices designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite. In 2024, it commenced commercialization activities for iDose TR, a long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time.

Written from the business description in GLAUKOS Corp's annual report to the U.S. Securities and Exchange Commission, filed 23 February 2026. Every sentence was checked against that document before publication.

Growth

USD 507.4M
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 507.4 · Net income -187.7
200M400M-100M-200M
20132016201920222025
Compound annual growth
+21.5%
+17.7%
+21.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +17.7% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−37 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -39.3% · Net -37.0%
-20%-40%-60%
201320192025
ROE
FY2025 · ROE -26.4%
2%4%-10%-20%
201320192025
Three returns, three denominators.

Each USD of equity lost 26 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -22.5
10M20M-30M-60M
201320192025
Net buybacks $ Dividends $
FY2013 · Dividends · · Net buybacks -30000.0
-15000-30000
2013

Total assetsUSD 893.5M
EquityUSD 656.2M
CashUSD 90.8M
Current ratio4.69×

Equity funds 73% of total assets.

The 13-year record

13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
GKOS, 13-year financial record
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.50.40.30.30.30.20.20.20.20.10.10.00.0
Operating income $B−0.2−0.1−0.1−0.1−0.0−0.1−0.1−0.0−0.00.0−0.0−0.0−0.0
EBITDA $B−0.2−0.1−0.1−0.1−0.0−0.1−0.0−0.00.00.0−0.0−0.0−0.0
Income tax $B−0.00.00.00.00.0−0.0−0.10.00.00.00.00.00.0
Net income $B−0.2−0.1−0.1−0.1−0.0−0.10.0−0.0−0.00.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.1−0.1−0.1−0.0−0.0−0.00.00.00.0−0.0−0.0−0.0
EPS, diluted $−3.28−2.77−2.78−2.09−1.07−2.700.37−0.370.000.12−2.13−5.29−6.21
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————
ROE %−26.4−23.8−27.2−17.8−7.9−18.03.6−8.3−0.14.3———
Shares out B0.060.060.050.050.050.050.040.040.030.030.030.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures · 1 divergence in 62 reconciliationsAUDITED

Reconciled in 12 of the 13 fiscal years we could check. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 14 checks were skipped: the balance sheet is not tagged before 2014. Six checks were skipped: EPS is not tagged before 2013. Six checks were skipped: revenue is not tagged before 2013.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures1 divergent
ActivitySurgical & Medical Instruments & Apparatus
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2013

Share this section

Download image